Imexpharm Corp operates within the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Imexpharm Corp with three other companies in this sector in Vietnam: Hatay Pharmaceutical JSC (2017 sales of 1.48 trillion Dong [US$64.99 million] ), DOMESCO Medical Import Export Joint Stock Corp (1.34 trillion Dong [US$58.81 million] ), and OPC Pharmaceutical JSC (961.73 billion Dong [US$42.22 million] ).

Sales Analysis. During the year ended December of 2017, sales at Imexpharm Corp were 1.17 trillion Dong (US$51.16 million). This is an increase of 15.4% versus 2016, when the company's sales were 1.01 trillion Dong. This was the fifth consecutive year of sales increases at Imexpharm Corp (and since 2012, sales have increased a total of 42%).